ALDR Alder BioPharmaceuticals, Inc.

20.75
+0  (1%)
Previous Close 20.45
Open 20.70
Price To book 2.69
Market Cap 1.05B
Shares 50,409,000
Volume 495,458
Short Ratio 15.29
Av. Daily Volume 576,202

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 3 PROMISE 2 initiation announced November 28, 2016. Data due 1H 2018.
ALD403 - PROMISE 2
Frequent episodic migraine
Phase 2b data released March 2016 met primary and secondary endpoints. 24 week data released July 2016.
ALD403
Chronic Migraine
Phase 3 PROMISE 1 topline data due 1H 2017.
ALD403 - PROMISE 1
Frequent episodic migraine

Latest News

  1. Alder BioPharmaceuticals to Host Conference Call to Discuss First Quarter 2017 Financial and Operating Results
  2. Alder BioPharmaceuticals Appoints Wendy L. Yarno to its Board of Directors
  3. Alder BioPharmaceuticals to Present at the 16th Annual Needham Healthcare Conference
  4. Alder Biopharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : ALDR-US : March 21, 2017
  5. Alder Biopharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : ALDR-US : March 9, 2017
  6. Alder BioPharmaceuticals Announces Presentations at 69th Annual American Academy of Neurology Meeting Supporting Development of Eptinezumab for Migraine Prevention
  7. Edited Transcript of ALDR earnings conference call or presentation 23-Feb-17 10:00pm GMT
  8. Alder BioPharmaceuticals posts 4Q loss
  9. Alder BioPharmaceuticals Announces Fourth Quarter and Full Year 2016 Financial and Operating Results
  10. Alder BioPharmaceuticals to Host Conference Call to Discuss Fourth Quarter and Full Year 2016 Financial and Operating Results
  11. Alder BioPharmaceuticals to Present at the Leerink Partners 6th Annual Global Healthcare Conference
  12. Alder Biopharmaceuticals, Inc. – Value Analysis (NASDAQ:ALDR) : February 8, 2017
  13. Alder Biopharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : ALDR-US : February 7, 2017
  14. Lilly Regains Key Migraine Drug With $960 Million CoLucid Acquisition
  15. Trump's 'Disastrous' Pharma View Doesn't Rattle JPMorgan Drug Conference
  16. Amgen Shares Skyrocket on Surprise Patent Victory, Plus Jim Cramer's View
  17. Migraine Biologics Drugs Has Blockbuster Potential
  18. Migraine drugs may repeat rheumatoid arthritis success
  19. Alder Biopharmaceuticals (ALDR) Sees Hammer Chart Pattern: Time to Buy?